JB Pharma to acquire four pediatric brands from Dr Reddy’s Labs for ₹98.3 crore

• All four brands have a combined market size of 1,800 crore and generated a whopping ₹33 crore in revenue in FY22.
• The pharmaceutical company will take over the manufacturing, marketing and distribution of these brands in India.
• The integration and transition of the brands is expected to be completed in the next two weeks.

KKR-backed JB Chemicals and Pharmaceuticals said it has acquired four pediatric brands – Z&D, Pedicloryl, Pecef and Ezinapi from dr. Reddy’s Laboratories†

The acquisition was made for a cash consideration of ₹98.3 crore, excluding working capital and taxes. All four brands have a combined market size of 1,800 crore and generated a whopping ₹33 crore in revenue in FY22.

“Overall, the acquired brands have significant growth potential to strengthen our already established presence in the pediatric category, which is synergistic with our current portfolio, depth of specialty and geographic presence,” said Nikhil ChopraCEO at JB Pharma†

Z&D produces zinc supplements that are used for boosting immunity. Pedicloryl oral solution is used in children in hospitals for idiopathic pain relief.

Pecef focuses on both bacterial infections and respiratory infections in children. Ezinapi cream is used as an emollient for diaper rash in infants.

JB Pharma will take over the production, marketing and distribution of these brands in India.

“It will also help us significantly leverage our strength in the field and broaden our offerings in the pediatric basket – comprising gut health and respiratory infections products for healthcare professionals across the country,” said Chopra.

The integration and transition of the brands is expected to be completed in the next two weeks.

“All four brands have a lion’s share in their respective spaces. We will continue to focus on evaluating opportunities to strengthen our domestic business in India,” Chopra added.

according to the media
reports, the pharmaceutical company is looking for companies to acquire in the domestic market. It had also acquired brands of Sanzyme – which trades in probiotics and reproductive health for ₹628 crore in January.

ALSO SEE:
Ambani and Adani valuations soar as Tatas and Birlas see big declines in the first half of 2022

Telecom company Parallel Wireless lays off 500 employees, including in India